Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Longitudinal Analysis of Patient Characteristics in Dupilumab Treatment for Atopic Dermatitis: Investigating Channeling Bias Following Pediatric Label Expansion

  • By

  • Julie Barberio

  • Venkatesh Harikrishnan

  • Shiyao Gao

  • Andrea Marcus

  • Sarah-Jo Sinnott

  • July 18, 2026

Share

Original Source(s)

Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension

  • by Julie Barberio, Venkatesh Harikrishnan, Shiyao Gao, Andrea Marcus, Sarah-Jo Sinnott

  • July 18, 2026

Related Content

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Medical Oddities: A fowl cause of urinary obstruction

A rogue chicken bone, stalled sweat, yoga for IBS, and L-theanine for sleep is break room fodder this week.